Compare KPTI & STKE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KPTI | STKE |
|---|---|---|
| Founded | 2008 | 2002 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.6M | 95.8M |
| IPO Year | 2013 | N/A |
| Metric | KPTI | STKE |
|---|---|---|
| Price | $6.53 | $2.52 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $22.17 | N/A |
| AVG Volume (30 Days) | 131.2K | ★ 211.2K |
| Earning Date | 11-03-2025 | 01-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $142,530,000.00 | $14,342,517.00 |
| Revenue This Year | $3.82 | $43.15 |
| Revenue Next Year | $3.18 | $39.60 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.51 | $2.07 |
| 52 Week High | $12.45 | $34.32 |
| Indicator | KPTI | STKE |
|---|---|---|
| Relative Strength Index (RSI) | 61.76 | N/A |
| Support Level | $5.70 | N/A |
| Resistance Level | $6.05 | N/A |
| Average True Range (ATR) | 0.41 | 0.00 |
| MACD | 0.10 | 0.00 |
| Stochastic Oscillator | 84.89 | 0.00 |
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
Sol Strategies Inc is engaged in investing in blockchain technologies and crypto currencies. Company executes its Investment Objective through three lines of effort: Treasury management: Maintaining a core portfolio of cryptocurrencies for long-term growth, enhanced with risk management strategies to minimize volatility, and generating yield through lending, staking, and liquidity provisioning; Private equity focused on early stage companies in the DeFi and blockchain sectors; and Active investments to generate yield through strategic activities, including Bitcoin mining and stalking and validating Solana.